Provided is a pharmaceutical composition for treating brain cancer or reducing temozolomide-resistance of brain cancer cells, comprising a pharmaceutically acceptable carrier and an effective amount of an active ingredient selected from the group consisting of (Z)-butylidenephthalide of formula (I)